efficacy and safety of  xxxd2190xxx  in patients with  xxxg382xxx -positive acute myeloid leukemia in first relapse.  three open-label, multicenter trials were conducted to evaluate the efficacy and safety of single-agent  xxxd2190xxx  ( xxxd2190xxx ;  xxxd2190xxx ; wyeth laboratories, philadelphia, pa), an antibody-targeted chemotherapy agent, in patients with  xxxg382xxx -positive acute myeloid leukemia (aml) in untreated first relapse.